Tandem Diabetes Care
TNDM
184 hedge funds and large institutions have $1.77B invested in Tandem Diabetes Care in 2018 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 12 closing their positions.
567% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 12
141% more capital invested
Capital invested by funds: $735M → $1.77B (+$1.03B)
129% more call options, than puts
Call options by funds: $91.9M | Put options by funds: $40.1M
59% more funds holding
Funds holding: 116 → 184 (+68)
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5.45% more ownership
Funds ownership: 66.7% → 72.15% (+5.5%)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.8M |
| 2 |
FAM
Fred Alger Management
New York
|
+$48.9M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$38.2M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$37.4M |
| 5 |
BlackRock
New York
|
+$34M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$80M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$57.3M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$41.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$36.6M |
| 5 |
O
OrbiMed
New York
|
-$34M |
TNDM Hedge Fund Activity: Q3 2018 in Review
184 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q3 2018, worth a combined $1.77B — up 141% from $735M a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new TNDM positions and 12 closed out — a net gain of 68 holders — while 57 added to existing stakes and 39 trimmed.
The largest buyer was Vanguard Group, adding an estimated $65.8M. The largest seller was Deerfield Management, cutting an estimated $80M.
- 184 institutional investors held Tandem Diabetes Care (TNDM) as of Q3 2018, up from 116 in Q2 2018.
- Funds reported $1.77B of Tandem Diabetes Care stock for Q3 2018, up 141% quarter-over-quarter.
- 80 funds opened new Tandem Diabetes Care positions in Q3 2018 and 12 closed out, a net change of +68 holders.
- The largest Tandem Diabetes Care buyer in Q3 2018 was Vanguard Group, an estimated $65.8M added.
- The largest Tandem Diabetes Care seller in Q3 2018 was Deerfield Management, an estimated $80M sold.
Based on aggregated 13F filings for Q3 2018.